Achilles Heel of Essential Anti-cancer Protein (IMAGE)
Caption
Postdoctoral researchers Muhan Chen, Dawid G. Nowak and others in the Trotman lab at CSHL may have solved a mystery about prostate cancer: why some patients appear to have low levels of the powerful tumor-suppressing protein PTEN and yet have no mutations in the gene that encodes the protein. The answer is implied in this image. In a sample of mouse prostate tissue on the way to becoming cancerous, they show one area in which PTEN protein levels are high (Area 1, yellow dashes) and a nearby area (Area 2, red dashes) where they are low. Where PTEN is low, so are levels of a protein called Importin 11 (Ipo11); where PTEN is abundant, so too is Ipo11. Ipo11 saves PTEN proteins marked for destruction by carrying them into the cell nucleus, perhaps in this way forming a "reservoir" and saving PTEN for future use in the battle against the emerging tumor. When Ipo11 is missing, cancer progression is promoted.
Credit
Trotman Lab, CSHL
Usage Restrictions
please give credit
License
Licensed content